| Ytd | 20.71% | |
| 1y | -29.29% |
| Open | 1.62 | Prev Close | 1.64 | Low | 1.62 | High | 1.69 | Mkt Cap | 78.54M |
| Vol | 234.41K | Avg Vol | 591.07K | EPS | -1.09 | P/E | N/A | Forward P/E | 2.57 |
| Beta | -0.73 | Short Ratio | 1.22 | Inst. Own | 0.75% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-16 | 50-d Avg | 1.64 | 200-d Avg | 1.59 | 1yr Est | 12.67 |
OSTX News
Up to $10 million debt financing supported by U.K. subsidiary VAT refunds and reimbursable R&D tax c
Meeting to occur in mid-September 2026Interim 3-year Overall Survival data expected early September,
Meeting to occur in mid-September 2026 Interim 3-year Overall Survival data expected early September
Roth Capital analyst Adam Walsh initiates coverage on OS Therapies (AMEX:OSTX) with a Buy rating
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader i
CDER meeting expected to take place in the summer of 2026 in parallel with CBER's Type B Statistical
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader i
Upcoming Type B Statistical Methods Meeting expected to set stage for FDA to align with EMA and MHRA
Company secures $10 million line of credit supported by OS Therapies UK tax credits New York, New Yo
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader i
Type B Meeting requested to follow up on September 2025 End of Phase 2 FDA Meeting guidance on stati
20% of OST-HER2 treated dogs survived 2-year vs. 1% in control group (p = 0.00995)Over 15,000 dogs p
20% of OST-HER2 treated dogs survived 2-year vs. 1% in control group (p = 0.00995) Over 15,000 dogs
Confirmatory Phase 3 trial to commence prior to BLA grant under Accelerated Approval Program in the
Confirmatory Phase 3 trial to commence prior to BLA grant under Accelerated Approval Program in the
OS Therapies Incorporated (NYSE:OSTX) shares are up during Tuesday's premarket session as the compan
OS Therapies shares rise after OST-HER2 Phase 2b data showed a 75% survival rate and progress toward
75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control (p = 0.003), with no ne
75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control (p = 0.003), with no ne
The Company confirms that it will release 2.5 year overall survival data from Phase 2b clinical tria
ASCO 2026: 2.5-Year Overall Survival Data Jefferies Healthcare Conference: Partnering & Investor mee
Lake Street analyst Chad Messer maintains OS Therapies (AMEX:OSTX) with a Buy and lowers the pric
OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.27) per share which missed the analyst con
$5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in
New York, New York and Rockville, Maryland--(Newsfile Corp. - May 15, 2026) - OS Therapies, Inc. (NY
Appointment strengthens medical, regulatory, and commercial leadership as Company prepares to comple
Dallas, Texas--(Newsfile Corp. - May 12, 2026) - OS Therapies Inc. (NYSE American: OSTX): Stonegate
Conference call scheduled for Thursday, April 30, 2026, at 8:30 am ET to review new OST-HER2 immune
Conference call scheduled for Thursday, April 30, 2026, at 8:30 am ET to review new OST-HER2 immune
Regulatory feedback recent from April 2026 EU EMA and Australian TGA meetings Remaining Q2-2026 regu
New patent application covers treatment-emergent immune signature related to 'turning cold tumor
New patent application covers treatment-emergent immune signature related to 'turning cold tumors ho
Co-founder of more than 40 biotechnology companies, including 16 IPOs and 19 successful acquisitions
OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.41) per share which missed the analyst con
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader i
Meetings with all four regulatory agencies scheduled to occur in the second quarter of 2026, with ex
FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated
OS Therapies shares climb after new regulatory plans for OST-HER2 osteosarcoma treatment in the UK,
D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:OSTX) with a Buy and maintain
OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in
OS Therapies releases trial data supporting FDA approval, U.K. and U.S. timelines, and potential eli
Activation of immune blood biomarkers from interferon gamma pathway distinguished long term survivor
D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:OSTX) with a Buy and maintain
OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in
D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:OSTX) with a Buy and maintain
FDA confirmed that data from single-arm studies in rare diseases, such as in ultra-rare deadly pedia